News Headlines

  1. Ajinomoto Bio-Pharma Services And Olon S.p.A. Form Strategic Partnership To Advance Large-Scale Peptide And Protein Manufacturing 10/28/2025

    Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Olon S.p.A. ("Olon") have entered into a strategic partnership to deliver innovative, large-scale drug substance manufacturing services to pharmaceutical and biotechnology clients, leveraging Aji Bio-Pharma's microbial CORYNEX® peptide and protein manufacturing platform and Olon's large-scale microbial fermentation capabilities.

  2. Lifecore And PolyPeptide Announce Collaboration Intended To Offer End-To-End Peptide Manufacturing Solution For U.S. Market 10/28/2025

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S.

  3. Hovione Completes Initial $100M Investment Cycle To Expand U.S. Operations At New Jersey Manufacturing Site 10/27/2025

    Hovione, a fully-integrated global CDMO, today announced the completion of an initial multi-million-dollar investment cycle to expand its manufacturing site in East Windsor, New Jersey.

  4. Curia Invests $4M To Enhance Sterile API Manufacturing 10/27/2025

    Curia, a leading global research, development and manufacturing organization, today announced the completion of a $4M investment to upgrade its two API aseptic suites in Valladolid, Spain.

  5. Simtra BioPharma Solutions Expands Global Manufacturing Footprint To Advance The Future Of Sterile Injectables 10/27/2025

    Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, is making progress on a dual-continent expansion strategy to meet growing global demand for complex, high-value therapies.

  6. Sai Life Sciences Set To Double Process R&D Capacity With New Facility In Hyderabad 10/27/2025

    Sai Life Sciences Limited, one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the groundbreaking for a new CMC Process R&D Center at its integrated R&D campus in Hyderabad.

  7. AGC Biologics Partners With Rarity PBC To Advance Life-Saving Gene Therapy For 'Bubble Baby Disease' 10/24/2025

    AGC Biologics announced an agreement with Rarity PBC to provide comprehensive development and GMP manufacturing for Rarity's gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder.

  8. Abolis Biotechnologies And EUROAPI Enter Into Partnership To Accelerate Pharmaceutical Innovation And Restore European Sovereignty 10/23/2025

    Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, today announced that it has entered into a strategic partnership with EUROAPI, one of the world’s leading producers of active pharmaceutical ingredients, for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients, particularly from the corticosteroid family.

  9. SK pharmteco Boosts Domestic Peptide Scale-Up With Investment In California Facility 10/23/2025

    SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1M investment in its Rancho Cordova facility to expand and equip a new lab and CGMP-Kilo-scale facility for Solid-Phase Peptide Synthesis (SPPS) and purification.

  10. Bora Pharmaceuticals Leverages State-Of-The-Art Isolator Production Line To Scale Supply Of Vital Oncology Therapy 10/23/2025

    Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, will leverage its Groninger FlexPro 50 Isolator Line for Vials & Pre-filled Syringes to continue to broaden patients’ access to lifesaving treatments and therapies.